Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development
Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra®. Sofdra is the first and only FDA-approved new chemical entity (NCE) for the treatment of primary axillary hyperhidrosis. Through this partnership, Piramal Pharma Solutions...
MS Pharma Announces Strategic Growth Investment from Olayan Financing Company
Strategic Partnership to Accelerate Growth in Saudi Arabia and Across the MENA Region AMMAN, Jordan and RIYADH, Saudi Arabia, May 18, 2026 /PRNewswire/ -- MS Pharma today announced that Olayan Financing Company (OFC) has made a minority equity investment in the company. This partnership brings strategic depth to MS Pharma's next phase of growth, underscoring its commitment to innovation,...
Earendil Labs Announces First Cohort Dosed in Phase I Study of Novel Biparatopic Antibody Targeting Thymic Stromal Lymphopoietin (TSLP)
WILMINGTON, Del., May 18, 2026 /PRNewswire/ -- Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, today announced the successful completion of cohort 1 dosing in a phase I clinical trial for a novel biparatopic antibody targeting Thymic Stromal Lymphopoietin (TSLP). HXN-1011 is a novel recombinant humanized biparatopic antibody directed against two distinct epitopes...
Lundbeck receives orphan drug designation in Japan for asedebart for the treatment of patients with congenital adrenal hyperplasia and Cushing’s disease
Congenital adrenal hyperplasia (CAH) and Cushing's disease (CD) are rare disorders characterized by excess adrenocorticotropic hormone (ACTH) produced in the brain1,2 Current treatments are limited by suboptimal disease control and treatment-related complications3,4 Asedebart (Lu AG13909) is a novel, investigational anti-ACTH monoclonal antibody targeting underlying disease pathology Proof-of-concept trials are currently ongoing to evaluate efficacy and safety of...
PAIR and Cambridge NeuroWorks launch new online neuroscience seminar series in May 2026
HONG KONG, May 18, 2026 /PRNewswire/ -- The PolyU Academy for Interdisciplinary Research (PAIR) of The Hong Kong Polytechnic University has joined forces with Cambridge NeuroWorks, UK, made up of nine partners including the University of Cambridge, to launch a new online seminar series in neuroscience. The inaugural seminar, delivered by Prof. Edward CHANG of the University of California,...
PolyU collaborates with global scholars and experts to promote modern healthcare and wellness
Close to 100 participants experience Taichi and Qigong HONG KONG, May 18, 2026 /PRNewswire/ -- The Research Centre for Chinese Medicine Innovation (RCMI) of The Hong Kong Polytechnic University (PolyU) hosted the "Symposium on Martial Arts: Bridging Art and Science" and two "Health Cultivation Workshops" on 8 and 9 May. The events aimed to advance research and application...
Johnson & Johnson Launches ‘Gut Tunnel’ Experience in Singapore to Highlight the Importance of Endoscopic Remission in IBD
New data presented at Digestive Disease Week 2026 reinforces endoscopic remission as being associated with long-term patient outcomes,, yet more than 60% of people with IBD have not heard of this key treatment goal., Anchoring World IBD Day, the interactive Gut Tunnel installation (18–21 May, Asia Square 2, Singapore) makes invisible inflammation...
Harbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate
Hu-mAtrIx™-Enabled Next-Generation ACVR2A/2B-Targeting Antibody Demonstrates Potential to Become a Best-in-Class Therapy for Obesity CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, May 18, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other disease areas, today announced preclinical data for LET003, its first next-generation ACVR2A/2B-targeting monoclonal antibody developed using...
WuXi AppTec Recognized as a Top-Performing Company on 2026 Dow Jones Best-in-Class World Index
SHANGHAI, May 18, 2026 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), has been selected for the 2026 Dow Jones Best-in-Class World Index (DJ BIC World Index, formerly Dow Jones Sustainability World Index), which recognizes the top-performing companies in each industry on long-term sustainability criteria. This recognition reflects progress that WuXi AppTec...
LOTTE Biologics Expands Antibody Manufacturing Agreement with Ottimo Pharma
SEOUL, South Korea, May 18, 2026 /PRNewswire/ -- LOTTE Biologics (Co-CEOs James Park and Yooyeol Shin) announce an expansion of its collaboration with Ottimo Pharma, an innovative biotech company developing one-of-a-kind PD-1/VEGFR2 dual-paratopic antibodies, reinforcing a growing strategic partnership. Building on the antibody development/manufacturing agreement signed in June last year, this continued engagement...
